Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50)

Abstract

Acute limb ischemia (ALI) occurs at a rate of 1.3% per year in patients with symptomatic peripheral arterial disease (PAD) without atrial fibrillation. Vorapaxar reduces ALI in patients with symptomatic PAD including PAD resulting from graft thrombosis and in-situ thrombosis.